NeuroOne Medical Technologies Corporation has appointed David Wambeke as Chief Business Officer, with the executive simultaneously purchasing one million shares of company stock. The dual announcement represents both a strategic leadership addition and a significant vote of confidence in the medical technology company's direction.
Wambeke will lead NeuroOne's drug delivery program while working closely with the executive team to advance clinical development and commercialization strategy. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders in targeted disease areas, and engaging prospective pharmaceutical partners to maximize the strategic value of the company's emerging drug delivery platform. He will also oversee investor relations and support strategic business development initiatives, including partnerships and other corporate transactions.
"David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO of NeuroOne. The company believes Wambeke will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.
Wambeke's background includes serving as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia, establishing and overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, mergers and acquisitions, and strategic transactions.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. "With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation."
The share purchase occurred at a price of $0.6704 per share, representing the closing price of NeuroOne's common stock on February 27, 2026. NeuroOne intends to use the net proceeds from this sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. In connection with the appointment, the company also granted Wambeke an inducement stock option to purchase 500,000 shares of common stock pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan.
For business and technology leaders monitoring the medical technology sector, this appointment signals NeuroOne's commitment to accelerating its commercialization strategy while expanding into adjacent therapeutic areas. The personal investment by the new executive demonstrates alignment with shareholder interests and confidence in the company's growth trajectory. NeuroOne's focus on neurological disorders represents a significant market opportunity, with the company's electrode technology platform offering combination diagnostic and therapeutic functions that could potentially reduce hospitalizations, lower costs, and improve patient outcomes. More information about the company's technology platform is available at https://nmtc1.com.
The implications of this leadership transition extend beyond corporate governance. For investors, the insider purchase at market price suggests confidence in the company's valuation and future prospects. For the healthcare industry, NeuroOne's expansion into drug delivery represents another convergence point between medical devices and pharmaceuticals, potentially creating new treatment paradigms for neurological conditions. The company's existing FDA-cleared products for epilepsy and trigeminal nerve applications provide a commercial foundation from which to expand into basivertebral ablation and spinal cord stimulation markets.
